RevaTis
ActiveSummary
RevaTis has been active since 2013 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.6m and a net result of -€620,715. Equity is growing by ~13.9% per year across the filed fiscal years. Its solvency ranks better than 73% of 50 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability0▼-46
Solvency87▼-6
Growth52▼-26
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €130,000 at 30 days acceptable
Liquidity short (current ratio 0.98 against 1.19 in 2024; short-term debt: 36.5% and cash: 9% of total assets), and 38% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
62%
Return on assets
-15.1%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-07-2026, 3 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
3 d early
2024
104 d late
2023
2 d early
2022
19 d early
2021
25 d early
2020
31 d late
2019
22 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 9 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
28-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Turnover
€0
EBIT margin
Not included in this filing
Net result
-€620,715▼ 137%
2024 · -€262,021
Working capital
-€22,546
2024 · €191,819
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Turnover€0
Operating result€66,950▼ 77.0%€83,153▲ 24.2%-€201,181-€237,941▼ 18.3%-€590,139▼ 148%
Net result€58,529above the sector's middle half▼ 79.2%€48,252above the sector's middle half▼ 17.6%-€222,319within the sector's middle half-€262,021below the sector's middle half▼ 17.9%-€620,715below the sector's middle half▼ 137%
Equity€1.5mabove the sector's middle half▲ 4.0%€2.5mabove the sector's middle half▲ 64.0%€2.7mwithin the sector's middle half▲ 10.1%€2.5mwithin the sector's middle half▼ 9.6%€2.6mabove the sector's middle half▲ 3.1%
Total assets€2.7mabove the sector's middle half▲ 6.6%€3.5mabove the sector's middle half▲ 32.8%€3.8mwithin the sector's middle half▲ 8.8%€3.6mwithin the sector's middle half▼ 5.1%€4.1mabove the sector's middle half▲ 13.1%
Debt€1.1m▲ 10.2%€1.0m▼ 8.9%€1.1m▲ 5.9%€1.2m▲ 6.2%€1.6m▲ 34.5%
Working capital€352,388▼ 34.7%€836,416▲ 137%€918,097▲ 9.8%€191,819▼ 79.1%-€22,546
Solvency57.2%within the sector's middle half▼ 1.4pp70.6%above the sector's middle half▲ 13.5pp71.4%above the sector's middle half▲ 0.8pp68.0%above the sector's middle half▼ 3.4pp62.0%within the sector's middle half▼ 6.0pp
Staff (FTE)4.5▲ 60.7%5.5▲ 22.2%5.6below the sector's middle half▲ 1.8%5.7below the sector's middle half▲ 1.8%4.9▼ 14.0%
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2025 Net result -137% on 2024. The accounts now follow the abbreviated schema, last year the full schema.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €590,139 in 2025 against €237,941 in 2024; the loss grows and 2025 has the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.1m
Fixed assets
€2.6m ▲ 8.0%
Current assets
€1.5m ▲ 22.1%
Equity and liabilities €4.1m
Equity
€2.6m ▲ 3.1%
Debt
€1.6m ▲ 34.5%
Debt's share of the balance-sheet total rises from 32.0% to 38.0%. Equity and debt are higher.
Key figures and ratios
EBITDA
-€283,695▼
2024 · €114,415
Cash flow
-€314,271▼
2024 · €90,336
Current ratio
0.98▼
2024 · 1.19
Quick ratio
0.87▼
2024 · 1.02
Debt to equity
0.61▲
2024 · 0.47
ROE
-24.3%▼
2024 · -10.6%
ROA
-15.1%▼
2024 · -7.2%
Interest coverage
-8.93▼
2024 · 4.35
Debt ≤ 1 year
€1.5m▲
2024 · €1.0m
Debt > 1 year
€60,272▼
2024 · €143,570
Income taxes
€613▼
2024 · €945
Staff costs
€416,306▼
2024 · €491,445
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 4,815 companies that looked in July 2024 the way this one looks now, 1.9% went bankrupt within 24 months and 88% are still going.
- Micro
- 10 to 20 years old
- solvency 30% or more
- a loss of 10% of the balance sheet or more
1.9%
went bankrupt
9.8%
stopped otherwise
88%
still going
A further 0.5% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.7% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 4,815 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Turnover70 | €0 | - | - | - | - | - |
| Goods, raw materials, services and sundry goods60/61 | €0 | - | - | - | - | - |
| Remuneration, social security and pensions62 | €244,358 | €333,204 | €425,950 | €491,445 | €416,306 | ▼ 15.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €216,800 | €264,414 | €349,517 | €352,356 | €306,445 | ▼ 13.0% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | - | €2,985 | - |
| Other operating charges640/8 | €1,405 | €7,385 | €220 | €960 | €1,006 | ▲ 4.7% |
| Non-recurring operating charges66A | - | - | €7,796 | - | - | - |
| Gross operating margin9900 | €529,514 | €688,155 | €582,301 | €606,821 | €136,602 | ▼ 77.5% |
| Operating profit (loss)9901 | €66,950 | €83,153 | -€201,181 | -€237,941 | -€590,139 | ▼ 148% |
| Financial income75/76B | - | - | €2,012 | €3,152 | €2,053 | ▼ 34.9% |
| Recurring financial income75 | - | - | €2,012 | €3,152 | €2,053 | ▼ 34.9% |
| Financial charges65/66B | €8,421 | €34,604 | €22,603 | €26,286 | €32,015 | ▲ 21.8% |
| Recurring financial charges65 | €8,421 | €29,020 | €22,603 | €26,286 | €31,775 | ▲ 20.9% |
| Non-recurring financial charges66B | - | €5,584 | - | - | €241 | - |
| Profit (loss) for the period before taxes9903 | €58,529 | €48,548 | -€221,773 | -€261,075 | -€620,102 | ▼ 138% |
| Income taxes67/77 | - | €296 | €546 | €945 | €613 | ▼ 35.1% |
| Profit (loss) for the period9904 | €58,529 | €48,252 | -€222,319 | -€262,021 | -€620,715 | ▼ 137% |
| Profit (loss) for the period to be appropriated9905 | €58,529 | €48,252 | -€222,319 | -€262,021 | -€620,715 | ▼ 137% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €2.7m | €3.5m | €3.8m | €3.6m | €4.1m | ▲ 13.1% |
| Formation expenses20 | €0 | - | €0 | €31,787 | €47,850 | ▲ 50.5% |
| Fixed assets21/28 | €1.6m | €2.0m | €2.0m | €2.4m | €2.6m | ▲ 8.0% |
| Intangible fixed assets21 | €1.1m | €1.4m | €1.6m | €1.3m | €1.5m | ▲ 17.1% |
| Tangible fixed assets22/27 | €173,295 | €103,326 | €58,453 | €88,005 | €60,744 | ▼ 31.0% |
| Plant, machinery and equipment23 | €172,047 | €103,326 | €57,400 | €85,437 | €59,360 | ▼ 30.5% |
| Furniture and vehicles24 | €1,248 | - | €1,054 | €2,568 | €1,384 | ▼ 46.1% |
| Financial fixed assets28 | €323,758 | €431,558 | €431,558 | €1.0m | €1.0m | = |
| Current assets29/58 | €1.1m | €1.6m | €1.8m | €1.2m | €1.5m | ▲ 22.1% |
| Stocks and contracts in progress3 | €86,155 | €273,522 | €346,902 | €175,218 | €177,686 | ▲ 1.4% |
| Stocks30/36 | €86,155 | €273,522 | €346,902 | €175,218 | €177,686 | ▲ 1.4% |
| Amounts receivable within one year40/41 | €391,761 | €717,702 | €771,411 | €546,264 | €881,461 | ▲ 61.4% |
| Trade receivables40 | €341,749 | €640,634 | €690,341 | €460,091 | €667,418 | ▲ 45.1% |
| Other amounts receivable41 | €50,012 | €77,069 | €81,070 | €86,173 | €214,043 | ▲ 148% |
| Cash at bank and in hand54/58 | €418,878 | €454,089 | €371,276 | €255,417 | €371,672 | ▲ 45.5% |
| Deferred charges and accrued income490/1 | €183,956 | €122,753 | €299,583 | €234,225 | €48,486 | ▼ 79.3% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €2.7m | €3.5m | €3.8m | €3.6m | €4.1m | ▲ 13.1% |
| Equity10/15 | €1.5m | €2.5m | €2.7m | €2.5m | €2.6m | ▲ 3.1% |
| Contributions10/11 | €2.4m | €3.0m | €3.5m | €3.5m | €4.2m | ▲ 20.5% |
| Capital10 | €1.1m | €1.2m | €1.3m | - | €1.4m | - |
| Issued capital100 | €1.1m | €1.2m | €1.3m | - | €1.4m | - |
| Uncalled capital101 | €2,500 | €2,500 | €0 | - | - | - |
| Outside capital11 | €1.3m | €1.8m | €2.2m | - | €2.8m | - |
| Share premium1100/10 | €1.3m | €1.8m | €2.2m | - | €2.8m | - |
| Revaluation surpluses12 | - | €257,800 | €257,800 | €257,800 | €257,800 | = |
| Profit (loss) carried forward14 | -€841,183 | -€792,931 | -€1.0m | -€1.3m | -€1.9m | ▼ 50.0% |
| Amounts payable17/49 | €1.1m | €1.0m | €1.1m | €1.2m | €1.6m | ▲ 34.5% |
| Amounts payable after more than one year17 | €407,813 | €302,845 | €224,392 | €143,570 | €60,272 | ▼ 58.0% |
| Financial debts170/4 | €407,813 | €302,845 | €224,392 | €143,570 | €60,272 | ▼ 58.0% |
| Amounts payable within one year42/48 | €728,363 | €731,650 | €871,075 | €1.0m | €1.5m | ▲ 47.3% |
| Current portion of amounts payable after more than one year42 | €45,693 | €19,942 | €0 | - | - | - |
| Financial debts43 | - | - | €125,000 | €400,000 | €489,555 | ▲ 22.4% |
| Credit institutions430/8 | - | - | €125,000 | €400,000 | €489,555 | ▲ 22.4% |
| Other loans439 | - | - | €0 | - | - | - |
| Trade debts44 | €440,309 | €462,917 | €565,382 | €391,489 | €585,442 | ▲ 49.5% |
| Suppliers440/4 | €440,309 | €462,917 | €565,382 | €391,489 | €585,442 | ▲ 49.5% |
| Advances received on contracts in progress46 | €60,000 | €48,267 | €48,267 | €48,267 | - | - |
| Taxes, remuneration and social security45 | €58,699 | €39,488 | €53,806 | €42,974 | €50,544 | ▲ 17.6% |
| Taxes450/3 | €35,181 | - | €0 | €0 | €0 | = |
| Remuneration and social security454/9 | €23,518 | €39,488 | €53,806 | €42,974 | €50,544 | ▲ 17.6% |
| Other amounts payable47/48 | €123,662 | €161,036 | €78,619 | €136,575 | €376,310 | ▲ 176% |
| Accrued charges and deferred income492/3 | - | - | - | - | €1,570 | - |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €58,529 | €48,252 | -€222,319 | -€262,021 | -€620,715 | ▼ 137% |
| + Depreciation and write-downs630 | €216,800 | €264,414 | €349,517 | €352,356 | €306,445 | ▼ 13.0% |
| Operating cash flow (approximation) | €275,329 | €312,666 | €127,199 | €90,336 | -€314,271 | ▼ 448% |
| Investment in fixed assets (approximation) | - | -€646,470 | -€439,564 | -€704,005 | -€498,809 | ▲ 29.1% |
| Change in cash | - | €35,211 | -€82,812 | -€115,860 | €116,256 | ▲ 200% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
28-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
17-07
State Gazette act
Appointments: SERTEYN Didier Daniel Alex (director) and MARTIN Jean-Luc (director)Power of attorney · Capital increase · Share issue14 facts ▸
State Gazette act
Appointments: SERTEYN Didier Daniel Alex (director) and MARTIN Jean-Luc (director)
Power of attorney · Capital increase · Share issue14 facts ▸
- General meeting, Assemblée générale extraordinaire
- Director appointment, SERTEYN Didier Daniel Alex (director)
- Director appointment, MARTIN Jean-Luc (director)
- Board meeting, 30-03-2026
- Board meeting, 26-05-2025
- Power of attorney, SERTEYN Didier Daniel Alex
- Power of attorney, MARTIN Jean-Luc
- Capital increase, €17.000
- Other statement, Suppression du droit de préférence, augmentation de capital en numéraire
- Share issue, souscription et libération, augmentation de capital en numéraire
- Capital, €1.450.000
- Other statement, Affectation en un compte indisponible « Prime d’émission », Prime d’émission
- +2 further facts in this act
2025
31-12
Financial
Weakest financial yearnet -€620,715
Net result drops to -€620,715, the lowest in the series.
12-11
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 104 days late
2024
29-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
12-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Equity above €2mEq €2.5m ▲64%
3 profitable years in a row build equity to €2.5m.
06-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 31 days late
2020
31-12
Financial
Back to profitnet €281,492
Net result €281,492 after 2 loss-making years.
31-12
Financial
Liquidity quadruplescurrent ratio 1.91
Current ratio from 0.48 to 1.91; short-term debt falls from €1.2m to €592,163.
31-12
Financial
Equity above €1mEq €1.5m ▲153%
Equity rises from €576,296 to €1.5m.
Show earlier events
09-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
01-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
05-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
12-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 26 acts read
About the unread acts
Of the 26 Belgian State Gazette acts we know for this company, 1 has been read. The other 25 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 directors, last change in 2020
Jean-Luc MARTIN
CurrentDirector · since 19-06-2020
SERTEYN Didier Daniel Alex
CurrentDirector · since 19-06-2020
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
25 of this company's 26 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Marche-en-Famenne · 1 establishment unit since 2013
Ground area
7,338 m²
Building footprint
2,212 m²
Parcel 83002A0999/00A031, Wallonia. Linked by address, not a title deed.
1 establishment unit
Aye, Rue de la Science 8, 6900 Marche-en-Famenne
since 20132.224.096.568
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 83002A0999/00A031 | Wallonia | 7,337 m² | 1 · 2,212 m² | - |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
2 people since 2020, 2 in office
- Board
| Name | Functions and periods |
|---|---|
| Jean-Luc MARTIN |
|
| SERTEYN Didier Daniel Alex |
|
Structure & network
Owners and holdings
2 ownersOwners 2
-
18.36%
-
3.7%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
9 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
BANQUE CPH
via Jean-Luc MARTIN · Administrateur non exécutif
→
Centre d'Orientation et de Formation
via Jean-Luc MARTIN · Director
→
Fonds et Services Sociaux - Réseau Solidaris
via Jean-Luc MARTIN · Daily management delegate
→
Mutualité Solidaris Wallonie
via Jean-Luc MARTIN · Director
→
Show 5 more companies with a shared director
Solidaris Coopérative
via Jean-Luc MARTIN · Director
→
Solidaris Immo
via Jean-Luc MARTIN · Director
→
CLASSDEAU
via Jean-Luc MARTIN · Director
former→
SOCIETE PUBLIQUE DE GESTION DE L'EAU
via Jean-Luc MARTIN · Président du comité de direction
former→
Société d'Investissement du Bassin liégeois
via Jean-Luc MARTIN · Class A director
former→
Similar companies · same sector, comparable size
White Raven
BE 0782.537.107
Liège · Eq €2,529,538
Advanced Practical Diagnostics
BE 0806.556.285
Turnhout · Eq €2,501,266
Ferring
BE 0428.038.135
Anderlecht · Eq €2,629,997
VERBERT
BE 0462.345.847
Antwerpen · Eq €2,651,366
UniD Manufacturing
BE 0736.939.187
Seraing · Eq €2,668,980
Of 148 companies in sector 21201 we hold annual accounts for 118. 66 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded06-11-2013
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
72101Research and development on biotechnology
Contact
Phone
0471/740876Marche-en-Famenne
E-invoicing
Reachable via Peppol
Peppol ID
0208:0541682642
Registered
20-11-2025
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.